1.Evaluation of clinical prognosis of liver transplant recipients of hepatocellular carcinoma complicated with microvascular invasion
Ziming LIANG ; Linsen YE ; Hui TANG ; Laien SONG ; Shijie GU ; Shuhong YI
Organ Transplantation 2020;11(3):350-
Objective To investigate the clinical prognosis of the liver transplant recipients diagnosed with hepatocellular carcinoma (HCC) complicated with microvascular invasion (MVI). Methods Clinical data of 3 447 HCC recipients undergoing liver transplantation were extracted from Surveillance, Epidemiology, and End Results (SEER) database of American National Cancer Institute. According to the incidence of MVI, all recipients were divided into MVI (
2.Peripheral blood immune cells in long-term survival patients after liver transplantation
Linsen YE ; Yingcai ZHANG ; Hui TANG ; Jia YAO ; Yunhao CHEN ; Yinan DENG ; Qi ZHANG ; Shuhong YI ; Hua LI ; Yang YANG ; Guihua CHEN
Chinese Journal of General Surgery 2017;32(6):508-511
Objective To explore the features of peripheral blood immune cells in long-term survival recipients after liver transplantation.Methods The expression of T subsets (Th1,Th2,Th17,Th22,Tregs),NK cells,NKt cells,Bregs,MDSC in long-term survival recipients (postoperative follow-up time ≥5 years,30 cases),short-term survival recipients(postoperative follow-up time ≤1 year,15 cases) and healthy control (15 cases) were determined by flowcytometry.Results Th17 cells were significantly higher in the long-term group compared with short-term group and healthy control group(P <0.01).Tregs in long-term group compared with short-term group were significantly higher (P < 0.01),but the difference was not statistically significant compared with healthy control group (P > 0.05).NK cells were significantly higher in long-term group compared with short-term group and healthy control group (P < 0.01).MDSC were significantly higher in long-term group compared with short-term group and healthy control group (P <0.01).Conclusions Th17,Tregs,NK cells and MDSC were significantly higher in long-term survival of liver recipients,which may be related to immune tolerance.
3.Establishment of a non-venous bypass orthotopic liver transplantation model in Bama miniature pigs
Qiao SU ; Zhenyu YU ; Wenwen LI ; Linsen YE ; Tianxing DAI ; Rongpu LIANG ; Rongqiang LIU ; Guozhen LIN ; Guangyin ZHAO ; Wuguo LI ; Guoying WANG ; Guihua CHEN
Organ Transplantation 2019;10(1):55-
Objective To establish a non-venous bypass orthotopic liver transplantation model in Bama miniature pigs with high repeatability and stability. Methods Twelve Bama miniature pigs were randomly divided into the donor group (
4.Clinical efficacy of hepatic arterial infusion chemotherapy combined with atelizumab plus bevacizumab on first line treatment of advanced hepatocellular carcinoma
Linsen YE ; Haoyuan YU ; Siqi LI ; Zhenyu YU ; Genshu WANG ; Yang LI
Chinese Journal of Digestive Surgery 2022;21(S1):5-9
The treatment of advanced hepatocellular carcinoma (HCC) is limited and the prognosis is poor, which seriously endangers the public health. Results of clinical trials have confirmed the validity of atelizumab plus bevacizumab in patients with advanced HCC. The authors introduce the clinical experience of a patient with stage Ⅲa HCC undergoing local therapy of hepatic artery chemoembolization, and combined with atelizumab plus bevacizumab. The results show that patient with successfully transformational therapy, and receiving surgical resection with a good clinical effect.
5.Application of artificial intelligence in liver transplantation
Zhixing LIANG ; Linsen YE ; Yang YANG
Journal of Clinical Hepatology 2022;38(1):30-34
With the advent of the era of 5G and big data, complex medical data with multiple dimensions and a large sample size bring both opportunities and challenges for clinical medicine in the new era. Compared with conventional methods, artificial intelligence can detect the hidden patterns within large datasets, and more and more scholars are applying such advanced technology in the diagnosis and treatment of diseases. After development and perfection for more than half a century, liver transplantation has become the most effective treatment method for end-stage liver diseases. Unlike the analysis of "single-patient" data in other fields, liver transplantation usually requires the consideration of the features of both the donor and the recipient and the variables during transplantation, thus generating a larger volume of medical data than other diseases, which is particularly in line with the advantages of artificial intelligence. Effective application of artificial intelligence and its combination with clinical research will usher in the new era of precision medicine. The advantages and limitations of artificial intelligence technology should be comprehensively discussed for the cross-application of artificial intelligence in liver transplantation, and the future directions of this field should also be proposed.